PreveCeutical Closes Initial Tranche of Up-Sized Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - April 28, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"),...
Concussion
Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference
SARASOTA, Fla., April 23, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing novel intranasal therapies...
PreveCeutical Announces Up-Sized Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - April 14, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company"...
Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial
SARASOTA, Fla., April 09, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel...
Rapid Dose Therapeutics Provides Update on the Clinical Trial Development and the Commitment to NFL Funded Cannabinoid Research
Burlington, Ontario--(Newsfile Corp. - April 8, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian biotech...
PreveCeutical Announces Update to Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - April 2, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company"...
Experience Onward Partners with Enthea to Expand Access to Psilocybin Treatment Through a Medical Tourism Benefit
Portland, Oregon--(Newsfile Corp. - April 2, 2025) - Experience Onward, Oregon's premier state-licensed psilocybin service center, is proud to announce...
Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress
ONP-002 Advances Toward Phase IIa Concussion Trial with Strengthened Financial Foundation and Industry MomentumSARASOTA, Fla., March 27, 2025 (GLOBE NEWSWIRE)...
AI is here. NSU forum explores how it will change business, healthcare and everything else
NATCHITOCHES, La., March 21, 2025 /PRNewswire/ -- "AI works 120 million times faster than the human brain," according to Dr....
New Psilocybin Service Center Opens to Support Athletes, Veterans, and Others with Traumatic Brain Injuries
Founded by Former NHL Player and mental health advocate Daniel Carcillo, the Portland center is the first of its kind...
PreveCeutical Announces Update to Private Placement
Vancouver, British Columbia--(Newsfile Corp. - March 10, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company"...
Header Restriction Policy in Youth Soccer Shows Promising Impact on Concussion Rates
SAN DIEGO, March 10, 2025 /PRNewswire/ -- A new study presented at the 2025 Annual Meeting of the American Academy...
Hemostemix and FireFly Neuroscience’s Brain Network Analytics (BNA(TM)) Engage to Complete Phase 1 Vascular Dementia Clinical Trial of ACP-01
A growing body of clinical evidence supports the use of Firefly's FDA-Cleared BNA(TM) platform to study ACP-01 as a treatment...
Sway Medical, Inc. Announces FDA 510(k) Clearance of its Comprehensive Concussion Management System
TULSA, Okla., Feb. 26, 2025 /PRNewswire/ -- Sway Medical, Inc., the company that created the Mobile Concussion Management category, is...
Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment
SARASOTA, Fla., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for...
Oragenics, Inc. Chief Medical Officer, Dr. James Kelly, Joins the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health
SARASOTA, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for...
Firefly Neuroscience Announces Exercise of Warrants for Total Proceeds of $8.8 Million
Extends cash runway well into mid-2026; no new/replacement warrants issuedKENMORE, N.Y., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc....
Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment
Collaboration Aims to Develop First Intranasal Therapy for Mild Traumatic Brain Injury Aka Concussion, Establishing a Comprehensive Test-to-Treat PlatformSARASOTA, Fla....
Firefly Neuroscience Accepted into NVIDIA Connect Program
Collaboration to provide Firefly with the technical resources to help further unleash the power of its FDA-cleared BNA™ platform For...
Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025
SARASOTA, Fla., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for...